Shares of Senores Pharma declined sharply by over 4% in trade, even as the company reported a robust set of financial results for the third quarter, marked by strong growth across revenue and profitability parameters. As of 1:45 PM, the shares were trading 3.70% lower at Rs 776.10.
For the December quarter, Senores Pharma posted a significant jump in net profit, which rose 88% year-on-year to ₹32 crore, compared with ₹17 crore in the same period last year.
Revenue performance remained strong, with Q3 revenue increasing 69.4% year-on-year to ₹174.5 crore, up from ₹103 crore in the corresponding quarter of the previous financial year. The growth reflects healthy execution across the company’s key business segments during the reporting period.
Operating metrics also showed notable improvement. EBITDA for the quarter stood at ₹54 crore, compared with ₹25.4 crore a year ago. As a result, EBITDA margins expanded to 31% from 25% on a year-on-year basis, indicating better cost efficiency and operating performance.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.